Generic placeholder image

Current Vascular Pharmacology

Author(s): Monica Verdoia*, Matteo Nardin, Rocco Gioscia, Andrea Rognoni and Giuseppe De Luca

DOI: 10.2174/0115701611280276240529105022

DownloadDownload PDF Flyer Cite As
Antiplatelet Effect of Low-Dose Prasugrel in Elderly Patients Undergoing Percutaneous Coronary Interventions

Page: [335 - 341] Pages: 7

  • * (Excluding Mailing and Handling)

Abstract

Background: Low-dose prasugrel (5 mg) has been proposed for patients with Acute Coronary Syndrome (ACS) and advanced age or low body weight. However, the routine use of dose-adjusted prasugrel in this high-risk subset of patients is still debated.

Aim: This study aimed to assess the prevalence and predictors of HRPR among elderly patients treated with low-dose (5 mg) prasugrel to evaluate the routine use of dose-adjusted prasugrel in this high-risk subset of patients.

Methods: We included 59 elderly patients (≥75 years) treated with Dual Antiplatelet Therapy (DAPT: acetylsalicylic acid (ASA) 100-160 mg + prasugrel 5 mg) after Percutaneous Coronary Interventions (PCI) and undergoing platelet function assessment (by whole blood impedance aggregometry) 30-90 days post-discharge.

Results: At a median follow-up of 43 days (interquartile range-IQR: 32-54), high-on treatment residual platelet reactivity (HRPR) occurred in 25 patients (42.4%), who displayed a greater body mass index (BMI) (p=0.02), lower levels of vitamin D (p=0.05) and were more frequently treated with nitrates (p=0.03). After multivariate analysis, BMI was the only independent predictor of prasugrel HRPR, and a BMI >26 was the best cut-off for predicting HRPR (adjusted Odds Ratio - OR=8.6, 95%CI: 2.2-33.9, p=0.002).

Conclusion: Among elderly patients receiving DAPT after PCI, HRPR is common with low-dose prasugrel. A greater BMI, especially for values ≥26, is the only independent predictor of HRPR with prasugrel 5 mg.

[1]
De Servi S, Landi A, Savonitto S, et al. Antiplatelet strategies for older patients with acute coronary syndromes: Finding directions in a low-evidence field. J Clin Med 2023; 12(5): 2082.
[http://dx.doi.org/10.3390/jcm12052082] [PMID: 36902869]
[2]
Andreotti F, Geisler T, Collet JP, et al. Acute, periprocedural and longterm antithrombotic therapy in older adults. Eur Heart J 2023; 44(4): 262-79.
[http://dx.doi.org/10.1093/eurheartj/ehac515] [PMID: 36477865]
[3]
Capodanno D, Angiolillo DJ. Antithrombotic therapy in the elderly. J Am Coll Cardiol 2010; 56(21): 1683-92.
[http://dx.doi.org/10.1016/j.jacc.2010.04.063] [PMID: 21070918]
[4]
Watanabe H, Morimoto T, Natsuaki M, et al. Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome. JAMA Cardiol 2022; 7(4): 407-17.
[http://dx.doi.org/10.1001/jamacardio.2021.5244] [PMID: 35234821]
[5]
Bortnick AE, Epps KC, Selzer F, et al. Five-year follow-up of patients treated for coronary artery disease in the face of an increasing burden of co-morbidity and disease complexity (from the NHLBI Dynamic Registry). Am J Cardiol 2014; 113(4): 573-9.
[http://dx.doi.org/10.1016/j.amjcard.2013.10.039] [PMID: 24388624]
[6]
Baber U, Mehran R, Giustino G, et al. Coronary thrombosis and major bleeding after PCI with drug-eluting stents. J Am Coll Cardiol 2016; 67(19): 2224-34.
[http://dx.doi.org/10.1016/j.jacc.2016.02.064] [PMID: 27079334]
[7]
Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357(20): 2001-15.
[http://dx.doi.org/10.1056/NEJMoa0706482] [PMID: 17982182]
[8]
Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel. J Thromb Haemost 2010; 8(1): 37-42.
[http://dx.doi.org/10.1111/j.1538-7836.2009.03644.x] [PMID: 19818001]
[9]
Silvain J, Cayla G, Hulot JS, et al. High on-thienopyridine platelet reactivity in elderly coronary patients: The sevior-platelet study. Eur Heart J 2012; 33(10): 1241-9.
[http://dx.doi.org/10.1093/eurheartj/ehr407] [PMID: 22067090]
[10]
Verdoia M, Pergolini P, Rolla R, et al. Advanced age and high- residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. J Thromb Haemost 2016; 14(1): 57-64.
[http://dx.doi.org/10.1111/jth.13177] [PMID: 26512550]
[11]
Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013; 62(24): 2261-73.
[http://dx.doi.org/10.1016/j.jacc.2013.07.101] [PMID: 24076493]
[12]
Ferri LA, Morici N, Grosseto D, et al. A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study. Am Heart J 2016; 181: 101-6.
[http://dx.doi.org/10.1016/j.ahj.2016.08.010] [PMID: 27823681]
[13]
Erlinge D, Gurbel PA, James S, et al. Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: The generations trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients. J Am Coll Cardiol 2013; 62(7): 577-83.
[http://dx.doi.org/10.1016/j.jacc.2013.05.023] [PMID: 23747759]
[14]
Roe MT, Goodman SG, Ohman EM, et al. Elderly patients with acute coronary syndromes managed without revascularization: Insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. Circulation 2013; 128(8): 823-33.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.002303] [PMID: 23852610]
[15]
Savonitto S, Ferri LA, Piatti L, et al. Comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization. Circulation 2018; 137(23): 2435-45.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.117.032180] [PMID: 29459361]
[16]
De Luca G, Verdoia M, Cassetti E, et al. High fibrinogen level is an independent predictor of presence and extent of coronary artery disease among Italian population. J Thromb Thrombolysis 2011; 31(4): 458-63.
[http://dx.doi.org/10.1007/s11239-010-0531-z] [PMID: 21080031]
[17]
De Luca G, Secco GG, Santagostino M, et al. Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study. Nutr Metab Cardiovasc Dis 2012; 22(5): 426-33.
[http://dx.doi.org/10.1016/j.numecd.2010.08.005] [PMID: 21186110]
[18]
Verdoia M, Sartori C, Pergolini P, et al. Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation. Vascul Pharmacol 2016; 77: 48-53.
[http://dx.doi.org/10.1016/j.vph.2015.04.014] [PMID: 25956733]
[19]
Verdoia M, Pergolini P, Camaro C, et al. PlA1/PlA2 polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty. Blood Coagul Fibrinolysis 2013; 24(4): 411-8.
[http://dx.doi.org/10.1097/MBC.0b013e32835d546e] [PMID: 23412353]
[20]
Vidali M, Rolla R, Parrella M, et al. Role of the laboratory in monitoring patients receiving dual antiplatelet therapy. Int J Lab Hematol 2012; 34(5): 484-94.
[http://dx.doi.org/10.1111/j.1751-553X.2012.01428.x] [PMID: 22613071]
[21]
Verdoia M, Pergolini P, Nardin M, et al. Prevalence and predictors of high-on treatment platelet reactivity during prasugrel treatment in patients with acute coronary syndrome undergoing stent implantation. J Cardiol 2019; 73(3): 198-203.
[http://dx.doi.org/10.1016/j.jjcc.2018.10.005] [PMID: 30522897]
[22]
Schoenenberger AW, Radovanovic D, Windecker S, et al. Temporal trends in the treatment and outcomes of elderly patients with acute coronary syndrome. Eur Heart J 2016; 37(16): 1304-11.
[http://dx.doi.org/10.1093/eurheartj/ehv698] [PMID: 26757786]
[23]
Savonitto S, Morici N, De Servi S. Update: acute coronary syndromes (VI): Treatment of acute coronary syndromes in the elderly and in patients with comorbidities. Rev Esp Cardiol 2014; 67(7): 564-73.
[http://dx.doi.org/10.1016/j.rec.2014.02.008] [PMID: 24952397]
[24]
Andreotti F, Rocca B, Husted S, et al. Antithrombotic therapy in the elderly: Expert position paper of the European society of cardiology working group on thrombosis. Eur Heart J 2015; 36(46): ehv304.
[http://dx.doi.org/10.1093/eurheartj/ehv304] [PMID: 26163482]
[25]
De Luca G, Verdoia M, Morici N, et al. Impact of hemoglobin levels at admission on outcomes among elderly patients with acute coronary syndrome treated with low-dose Prasugrel or clopidogrel: A sub-study of the ELDERLY ACS 2 trial. Int J Cardiol 2022; 369: 5-11.
[http://dx.doi.org/10.1016/j.ijcard.2022.07.033] [PMID: 35907504]
[26]
Alexopoulos D, Xanthopoulou I, Storey RF, et al. Platelet reactivity during ticagrelor maintenance therapy: A patient-level data meta-analysis. Am Heart J 2014; 168(4): 530-6.
[http://dx.doi.org/10.1016/j.ahj.2014.06.026] [PMID: 25262263]
[27]
Patti G, Cavallari I, Antonucci E, et al. Prevalence and predictors of dual antiplatelet therapy prolongation beyond one year in patients with acute coronary syndrome. PLoS One 2017; 12(10): e0186961.
[http://dx.doi.org/10.1371/journal.pone.0186961] [PMID: 29059255]
[28]
Gurbel PA, Erlinge D, Ohman EM, et al. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA 2012; 308(17): 1785-94.
[http://dx.doi.org/10.1001/jama.2012.17312] [PMID: 23117779]
[29]
Parodi G, Bellandi B, Comito V, et al. Residual platelet reactivity and outcomes with 5 mg prasugrel therapy in elderly patients undergoing percutaneous coronary intervention. Int J Cardiol 2014; 176(3): 874-7.
[http://dx.doi.org/10.1016/j.ijcard.2014.08.002] [PMID: 25139323]
[30]
Cayla G, Cuisset T, Silvain J, et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): An open-label, blinded-endpoint, randomised controlled superiority trial. Lancet 2016; 388(10055): 2015-22.
[http://dx.doi.org/10.1016/S0140-6736(16)31323-X] [PMID: 27581531]
[31]
Pankert M, Quilici J, Loundou AD, et al. Impact of obesity and the metabolic syndrome on response to clopidogrel or prasugrel and bleeding risk in patients treated after coronary stenting. Am J Cardiol 2014; 113(1): 54-9.
[http://dx.doi.org/10.1016/j.amjcard.2013.09.011] [PMID: 24182762]
[32]
Jakubowski JA, Angiolillo DJ, Zhou C, et al. The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: A retrospective analysis of the FEATHER study. Thromb Res 2014; 134(3): 552-7.
[http://dx.doi.org/10.1016/j.thromres.2014.05.019] [PMID: 25022828]
[33]
Mayer K, Orban M, Bernlochner I, et al. Predictors of antiplatelet response to prasugrel during maintenance treatment. Platelets 2015; 26(1): 53-8.
[http://dx.doi.org/10.3109/09537104.2013.863857] [PMID: 24433187]
[34]
Zaccardi F, Pitocco D, Willeit P, Laukkanen JA. Efficacy and safety of P2Y12 inhibitors according to diabetes, age, gender, body mass index and body weight: Systematic review and meta-analyses of randomized clinical trials. Atherosclerosis 2015; 240(2): 439-45.
[http://dx.doi.org/10.1016/j.atherosclerosis.2015.04.015] [PMID: 25897998]
[35]
De Luca G, Verdoia M, Savonitto S, et al. Impact of body mass index on clinical outcome among elderly patients with acute coronary syndrome treated with percutaneous coronary intervention: Insights from the ELDERLY ACS 2 trial. Nutr Metab Cardiovasc Dis 2020; 30(5): 730-7.
[http://dx.doi.org/10.1016/j.numecd.2020.01.001] [PMID: 32127336]
[36]
Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 2005; 294(24): 3108-16.
[http://dx.doi.org/10.1001/jama.294.24.3108] [PMID: 16380591]
[37]
Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107(23): 2908-13.
[http://dx.doi.org/10.1161/01.CIR.0000072771.11429.83] [PMID: 12796140]
[38]
Paniccia R, Antonucci E, Maggini N, et al. Assessment of platelet function on whole blood by multiple electrode aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy. Am J Clin Pathol 2009; 131(6): 834-42.
[http://dx.doi.org/10.1309/AJCPTE3K1SGAPOIZ] [PMID: 19461090]